Biophysics of Cryoballoon Ablation in Atrial Fibrillation
Experts in Electrophysiology will showcase the science and evidence behind cryoballoon pulmonary vein isolation and highlight the unique features cryo energy offers. Practical images and videos will be included to visualize the cryo biophysics. In addition, the presenters will draw on their clinical experience for an in-depth discussion on lesion durability and outcomes with cryoballoon AF ablation. Finally, the faculty will discuss their dosing protocol in light of their understanding of cryo biophysics.
The first Arctic Front Cardiac Cryoablation procedure took place in 2005 and since then, over 400,000 patients have been treated with cryoballoon in over 1,600 centers worldwide. The efficiency benefits of this unique single-shot therapy are obvious and well documented in the more than 600 peer-reviewed scientific articles. The results of the recent FIRE AND ICE and CRYO4PERSISTENT AF trials highlight an important global shift to value-based healthcare, measured by the ability to standardize the index PVI procedure. The impact on patient outcomes as well as the economic value for the global healthcare systems is significant.
Jason G Andrade
Roland R Tilz
This webinar is supported by
Key Learning Objectives
- science and evidence behind cryoballoon PVI.
- cryo lesion creation in comparison with other energy sources.
- latest dosing protocol with cryoballoon ablation.
- tips and techniques to improve outcomes with cryoballoon therapy.
- Cardiac electrophysiologists and allied health professionals performing and assisting during cryoballoon AF ablation procedures.
- Healthcare professionals using alternative AF ablation techniques and referring healthcare professionals treating AF patients will also find this topical.
Jason G Andrade
Dr Jason Andrade is a Cardiac Electrophysiologist at Vancouver General Hospital in Canada, with joint appointment at St Paul’s Hospital and the Montreal Heart Institute. He is an Associate Professor of Medicine at the University of British Columbia (UBC), and an Adjunct Professor at the Université de Montréal. Dr Andrade is the Director of the Electrophysiology Program at VGH, as well as Head of the Atrial Fibrillation Clinic at VGH. He also serves as co-chair of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines committee, and serves as the medical lead for the atrial fibrillation care in the province of British Columbia. He previously served as chair of the education committee for the Canadian Heart Rhythm society.
Dr Andrade is the principal investigator of two ongoing multicenter clinical trials on cryoablation (the CIRCA-DOSE study and the EARLY-AF program). He has authored or co-authored over 120 scientific publications, predominantly in the domain of atrial fibrillation. He is also the author of a handbook of cardiac electrophysiology, a handbook of electrocardiogram interpretation, and several chapters related to atrial fibrillation ablation and cardiac cryoablation.
Dr Andrade is a graduate of McMaster University (BSc; Summa Cum Laude) and the University of Ottawa (MD, Magna Cum Laude). He completed his Internal Medicine residency and Cardiology fellowship training at the University of British Columbia and a clinical and research fellowship in Cardiac Electrophysiology at the Montreal Heart Institute.
Roland R Tilz
Prof Roland Tilz is the deputy director of the Medical Center II of the University Hospital in Lübeck and professor of the invasive electrophysiology at the University Lübeck. He is committed to training in the field of “Invasive electrophysiology and cardiac rhythm implants”. Prof Roland Tilz trained at the Addenbrooks Hospital in Cambridge (UK), Bedford Hospital (UK), Klinikum Bayreuth and at the Asklepios Klinik St. Georg in Hamburg.
Prof Schilling has been a consultant cardiologist at St Bartholomew’s and the Royal London NHS trust since 2001. He was appointed as chair in cardiology and electrophysiology in 2009. His current practice involves all aspects of electrophysiology and management of cardiac arrhythmia including catheter ablation, implantation of pacemakers and cardiac defibrillators, and cardiac resynchronization therapy for heart failure patients.
Prof Schilling was part of the team that lead the merger of the Heart and Barts hospitals which is one of the largest heart centers in Europe. He is the Strategy Director for Barts Hospital, the Medical Director for the Arrhythmia Alliance and President-Elect for the British Heart Rhythm Society.
Prof Schilling is a member of the AER editorial board.